ATE474830T1 - Chromenderivate mit anti-tubulin- und gefässabzielender wirkung - Google Patents

Chromenderivate mit anti-tubulin- und gefässabzielender wirkung

Info

Publication number
ATE474830T1
ATE474830T1 AT05760509T AT05760509T ATE474830T1 AT E474830 T1 ATE474830 T1 AT E474830T1 AT 05760509 T AT05760509 T AT 05760509T AT 05760509 T AT05760509 T AT 05760509T AT E474830 T1 ATE474830 T1 AT E474830T1
Authority
AT
Austria
Prior art keywords
well
vassolar
tubulin
chrome
compounds
Prior art date
Application number
AT05760509T
Other languages
English (en)
Inventor
Kevin Pinney
Phyllis Arthasary
Anupama Shirali
Klaus Edvardsen
David J Chaplin
Original Assignee
Oxigene Inc
Univ Baylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/837,841 external-priority patent/US20050245489A1/en
Application filed by Oxigene Inc, Univ Baylor filed Critical Oxigene Inc
Application granted granted Critical
Publication of ATE474830T1 publication Critical patent/ATE474830T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05760509T 2004-05-03 2005-05-03 Chromenderivate mit anti-tubulin- und gefässabzielender wirkung ATE474830T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/837,841 US20050245489A1 (en) 2004-05-03 2004-05-03 Chromene-containing compounds with anti-tubulin and vascular targeting activity
US10/851,445 US7456214B2 (en) 2004-05-03 2004-05-21 Chromene-containing compounds with anti-tubulin and vascular targeting activity
PCT/US2005/015276 WO2005113532A1 (en) 2004-05-03 2005-05-03 Chromene-derivatives with anti-tubulin and vascular targeting activity

Publications (1)

Publication Number Publication Date
ATE474830T1 true ATE474830T1 (de) 2010-08-15

Family

ID=35045098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05760509T ATE474830T1 (de) 2004-05-03 2005-05-03 Chromenderivate mit anti-tubulin- und gefässabzielender wirkung

Country Status (5)

Country Link
US (1) US7456214B2 (de)
EP (1) EP1751128B1 (de)
AT (1) ATE474830T1 (de)
DE (1) DE602005022435D1 (de)
WO (1) WO2005113532A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46558E1 (en) 2005-04-28 2017-09-26 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
EP1984333B1 (de) 2006-02-03 2012-04-25 Bionomics Limited Substituierte benzofurane, benzothiophene, benzoselenophene und indole und ihre verwendung als tubulinpolymerisationsinhibitoren
CA2643579C (en) * 2006-02-28 2018-05-15 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
WO2009072915A1 (en) * 2007-12-05 2009-06-11 Bial - Portela & Ca., S.A. New salts and crystal forms
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
MX2010010431A (es) * 2008-03-25 2010-11-25 Paloma Pharmaceuticals Inc Metodos para tratar desordenes fibroticos.
AU2010286343B2 (en) 2009-08-27 2016-08-04 Bionomics Limited Treatment of macular degeneration
ES2545340T3 (es) 2009-08-27 2015-09-10 Bionomics Limited Terapia de la combinación para el tratamiento de enfermedades proliferativas
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
IT1212882B (it) * 1983-07-29 1989-11-30 Della Valle Francesco Derivati basici della cumarina
JPH07103164B2 (ja) * 1987-02-27 1995-11-08 三菱化学株式会社 光重合性組成物
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US6277879B1 (en) * 1994-08-03 2001-08-21 Sarawak Medichem Pharmaceuticals, Inc. Calanolide analogues and methods of their use
US5532382A (en) * 1995-03-13 1996-07-02 Eli Lilly And Company Benzothiophenes substituted at the 3-carbonyl
US6545027B1 (en) 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
CA2214070C (en) * 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
CA2215647A1 (en) * 1996-10-24 1998-04-24 Eli Lilly And Company Naphthyl compounds, compositions, and methods
US5886025A (en) * 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
NZ501822A (en) 1997-10-02 2001-12-21 Yukijirushi Nyugyo Kabushiki K Therapeutic agents for male and female sex hormone dependent diseases
WO1999034788A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
US6162930A (en) * 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
DE19937772A1 (de) * 1999-08-10 2001-02-15 Bayer Ag Substituierte Heterocyclyl-2GH-chromene
AU777725B2 (en) 1999-09-17 2004-10-28 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
WO2001068654A2 (en) 2000-03-10 2001-09-20 Baylor University Tubulin binding ligands and corresponding prodrug constructs
AU2001240985B2 (en) 2000-04-07 2005-08-04 Pfizer Products Inc. Estrogen agonist/antagonist metabolites
EP1276725A2 (de) 2000-04-17 2003-01-22 Warner-Lambert Company 5-substituierte tetralonen als ras farnesyl inhibitoren
CA2407672A1 (en) 2000-04-27 2001-11-01 Matthew P. Grealish Hydroxyphenstatin and the prodrugs thereof
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
WO2002060887A2 (en) 2001-02-01 2002-08-08 Thomas Jefferson University Synthesis of 4h-chromene derivatives
WO2003070159A2 (en) 2001-11-16 2003-08-28 Sarawak Medichem Pharmaceuticals Novel coumarin and chromene compounds and methods of treating or preventing viral infections
AU2003241482A1 (en) 2002-05-16 2003-12-02 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2003245935A1 (en) 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells

Also Published As

Publication number Publication date
EP1751128B1 (de) 2010-07-21
US7456214B2 (en) 2008-11-25
DE602005022435D1 (de) 2010-09-02
WO2005113532A1 (en) 2005-12-01
US20050245490A1 (en) 2005-11-03
EP1751128A1 (de) 2007-02-14

Similar Documents

Publication Publication Date Title
ATE474830T1 (de) Chromenderivate mit anti-tubulin- und gefässabzielender wirkung
WO2006138427A3 (en) Combretastatin analogs with tubulin binding activity
DE602005025803D1 (de) Stereoisomerisch angereicherte 3-aminocarbonyl-bicyclohepten-pyrimidindiamin-verbindungen und ihre verwendungen
UA96565C2 (ru) Пиридильные ингибиторы хеджхоговской передачи сигнала
BRPI0717266A2 (pt) Derivados de oxindol
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
WO2007008200A8 (en) Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
JP2006504723A5 (de)
SE531352C8 (sv) Spiroalkanderivat och användning av dessa föreningar för behandling av artrit, cancer, kardiovaskulära sjukdomar, hudsjukdomar och inflammatoriska och allergiska tillstånd
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2006110638A3 (en) Inhibitors of akt activity
MXPA06003222A (es) Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
NO20050640L (no) Rutenium anticancer komplekser
WO2001078783A3 (en) Compositions comprising natural agents for treatment of cancer
WO2001074376A3 (en) Cathepsin inhibitors in cancer treatment
WO2008002460A3 (en) Orally available light-independent antineoplastic compounds
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
DE60228544D1 (de) Triptolid-prodrugs zur krebstherapie
WO2003090680A3 (en) Novel phenyl derivatives as inducers of apoptosis
EA201000141A1 (ru) Новые триазены для лечения рака
WO2007051119A8 (en) Methods and compositions of parp inhibitors as potentiators in cancer therapy
EA200971103A1 (ru) Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами
DK1866292T3 (da) Tricykliske 1,2,4-triazinoxider og sammensætninger deraf til terapeutisk anvendelse i cancerbehandlinger
EA200900552A1 (ru) Пирроло[1,2-а]имидазолдион, эффективный при лечении периферической нейротоксичности, индуцированной химиотерапевтическими агентами

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties